Surufatinib plus FOLFOX/FOLFIRI shows potential in mCRC second-line therapy
A randomized phase-II trial is assessing surufatinib combined with FOLFOX/FOLFIRI against FOLFOXIRI for mCRC.
Phase III
metastatic colorectal cancer
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of surufatinib in combination with established chemotherapy regimens could significantly alter treatment paradigms in metastatic colorectal cancer. If successful, it may provide a competitive edge against existing therapies, necessitating close observation of trial outcomes and regulatory responses.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety outcomes, as well as subsequent regulatory decisions.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.